Charles River Laboratories’s (NYSE:CRL) Q2 CY2026 Sales Top Estimates, Stock Soars
Charles River Laboratories (NYSE:CRL) reported Q2 CY2026 results. Revenue fell 2.7% year on year to $1.00 billion but beat Wall Street estimates by 2.5%, according to the company. Non-GAAP adjusted EPS was $3.02, up 10.6% versus consensus. The stock rose 5.1% to $246.00. Analysts expect revenue to decline 3.9% and full-year EPS to rise from $9.90 to $12.15.
How this was made
The 30-second read
Why it matters
Q2 results show a mixed fundamental picture: revenue and EPS beat estimates, but YoY revenue declined and profitability contracted, while forward revenue expectations remain negative.
Market read
Traders can use the reported beat versus consensus and the immediate +5.1% reaction to gauge near-term sentiment, while monitoring margin contraction and the cited forward revenue decline for follow-through risk.
What to watch
Adjusted operating margin dropped sharply to 13.9% and the article cites expected revenue decline of 3.9% over the next 12 months, which could dominate after the initial post-earnings bounce.
Background
Charles River Laboratories provides non-clinical drug development services and research models to pharma and biotech clients.
Ticker impact
Charles River Laboratories reported Q2 CY2026 revenue of $1.00B, down 2.7% YoY, but 2.5% above Wall Street estimates, and adjusted EPS of $3.02 beat consensus.
Near-term upside bias from the reported beat, but follow-through may be capped by the stated expectation of revenue decline over the next 12 months.
The article provides a concrete earnings beat and an immediate post-report stock move (+5.1%), but also highlights YoY revenue decline, margin contraction, and expected revenue deterioration, which can limit sustained re-rating.
Market effects
Signals demand softness and margin pressure in non-clinical lab services, which can influence read-across sentiment for healthcare services peers.
Primarily US-listed single-name impact; limited regional spillover implied.
Global pharma services demand backdrop is referenced via organic revenue declines, but no specific global event is disclosed.
Counterpoint
The revenue beat may be more about estimate positioning than underlying acceleration, since YoY sales fell and organic revenue averaged declines over two years.
Key entities
- companyCharles River Laboratories
Non-clinical drug development services provider reporting Q2 CY2026 results.
- market_referenceWall Street estimates
Analyst consensus revenue and EPS expectations referenced in the article.
